- Home
- AQMS vs MYNZ Comparison
AQMS vs MYNZ Comparison
Compare AQMS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQMS
- MYNZ
- Stock Information
- Founded
- AQMS 2014
- MYNZ 2021
- Country
- AQMS United States
- MYNZ Germany
- Employees
- AQMS N/A
- MYNZ N/A
- Industry
- AQMS Metal Fabrications
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- AQMS Industrials
- MYNZ Health Care
- Exchange
- AQMS Nasdaq
- MYNZ Nasdaq
- Market Cap
- AQMS 18.0M
- MYNZ 15.3M
- IPO Year
- AQMS 2015
- MYNZ 2021
- Fundamental
- Price
- AQMS $2.01
- MYNZ $0.21
- Analyst Decision
- AQMS Strong Buy
- MYNZ Buy
- Analyst Count
- AQMS 2
- MYNZ 2
- Target Price
- AQMS $30.00
- MYNZ $3.00
- AVG Volume (30 Days)
- AQMS 106.9K
- MYNZ 5.4M
- Earning Date
- AQMS 11-14-2024
- MYNZ 10-21-2024
- Dividend Yield
- AQMS N/A
- MYNZ N/A
- EPS Growth
- AQMS N/A
- MYNZ N/A
- EPS
- AQMS N/A
- MYNZ N/A
- Revenue
- AQMS N/A
- MYNZ $917,203.00
- Revenue This Year
- AQMS N/A
- MYNZ $36.69
- Revenue Next Year
- AQMS N/A
- MYNZ $91.67
- P/E Ratio
- AQMS N/A
- MYNZ N/A
- Revenue Growth
- AQMS 525.00
- MYNZ 16.23
- 52 Week Low
- AQMS $1.33
- MYNZ $0.19
- 52 Week High
- AQMS $18.80
- MYNZ $1.79
- Technical
- Relative Strength Index (RSI)
- AQMS 18.44
- MYNZ 40.88
- Support Level
- AQMS $1.33
- MYNZ $0.21
- Resistance Level
- AQMS $2.15
- MYNZ $0.23
- Average True Range (ATR)
- AQMS 0.26
- MYNZ 0.04
- MACD
- AQMS -0.06
- MYNZ -0.00
- Stochastic Oscillator
- AQMS 7.48
- MYNZ 6.88
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.